Clinical manifestations and prognostic factors of Morganella morganii bacteremia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 231-236

  Lin, T Y ^a   Chan, M C ^a   Yang, Y S ^a   Lee, Y ^a   Yeh, K M ^a   Lin, J C ^a   Chang, F Y ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AGE; AGED; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BACTEREMIA; COMMUNITY ACQUIRED INFECTION; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORGANELLA MORGANII; MORTALITY; RISK FACTOR; TAIWAN; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENTAMICINS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORGANELLA MORGANII; PENICILLANIC ACID; PIPERACILLIN; RISK FACTORS; TAIWAN;

EID: 84939873946     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2222-8     Document Type: Article

References (20)

1. Abbott SL (2003) Enterobacteriaceae: introduction and identification. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds) Manual of clinical microbiology, 10th edn. American Society for Microbiology Press, Washington, pp 639–657
2. O’Hara CM, Brenner FW, Miller JM (2000) Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 13:534–546
3. Lee IK, Liu JW (2006) Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia. J Microbiol Immunol Infect 39:328–334
4. Gautam V, Gupta V, Joshi RM, Sawhney G, Duhan S (2003) Morganella morganii-associated arthritis in a diabetic patient. J Clin Microbiol 41:3451
5. Samonis G, Anatoliotaki M, Apostolakou H, Souglakos J, Georgoulias V (2001) Fatal septicemia and meningitis due to Morganella morganii in a patient with Hodgkin’s disease. Scand J Infect Dis 33:553–555
6. Johnson JR, Feingold M (1998) Case of chorioamnionitis in an immunocompetent woman caused by Morganella morganii. J Matern Fetal Med 7:13–14
7. Chang HY, Wang SM, Chiu NC, Chung HY, Wang HK (2011) Neonatal Morganella morganii sepsis: a case report and review of the literature. Pediatr Int 53(1):121–123
8. Arranz-Caso JA, Cuadrado-Gomez LM, Romanik-Cabrera J, García-Tena J (1996) Pyomyositis caused by Morganella morganii in a patient with AIDS. Clin Infect Dis 22:372–373
9. Chou YY, Chiu SK, Lai HC, Chang FY (2009) Tubo-ovarian abscess with Morganella morganii bacteremia. J Microbiol Immunol Infect 42(4):357–359
10. Farmer JJ III (2003) Enterobacteriaceae. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 7th edn. Churchill Livingstone, New York, pp 438–449
11. National Committee for Clinical Laboratory Standards (NCCLS) (1999) Performance standards for antimicrobial susceptibility testing. 9th informational supplement. NCCLS document M100-S9. NCCLS, Wayne, PA
12. Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J (2003) Bacteraemia due to tribe Proteeae: a review of 132 cases during a decade (1991–2000). Scand J Infect Dis 35:98–103
13. Falagas ME, Kavvadia PK, Mantadakis E, Kofteridis DP, Bliziotis IA, Saloustros E, Maraki S, Samonis G (2006) Morganella morganii infections in a general tertiary hospital. Infection 34:315–321
14. Williams EW, Hawkey PM, Penner JL, Senior BW, Barton LJ (1983) Serious nosocomial infection caused by Morganella morganii and Proteus mirabilis in a cardiac surgery unit. J Clin Microbiol 18:5–9
15. Gebhart-Mueller Y, Mueller P, Nixon B (1998) Unusual case of postoperative infection caused by Morganella morganii. J Foot Ankle Surg 37:145–147
16. Tessier F, Arpin C, Allery A, Quentin C (1998) Molecular characterization of a TEM-21 beta-lactamase in a clinical isolate of Morganella morganii. Antimicrob Agents Chemother 42:2125–2127
17. Perilli M, Segatore B, de Massis MR, Riccio ML, Bianchi C, Zollo A, Rossolini GM, Amicosante G (2000) TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob Agents Chemother 44:2537–2539
18. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ (1997) The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 24(Suppl 1):S46–S62
19. Modakkas EM, Sanyal SC (1998) Imipenem resistance in aerobic gram-negative bacteria. J Chemother 10:97–101
20. Singla N, Kaistha N, Gulati N, Chander J (2010) Morganella morganii could be an important Intensive Care Unit pathogen. Indian J Crit Care Med 14:154–155